Treatment of Advanced Postmenopausal Breast Cancer with an Aromatase Inhibitor, 4-Hydroxyandrostenedione: Phase II Report

Paul E. Goss, Trevor J. Powles, Mitchell Dowsett, Gillian Hutchison, Angela M. H. Brodie, Jean-Claude Gazet, and R. Charles Coombes

Cancer Research Campaign Laboratory (P. E. G.), Royal Marsden Hospital (T. J. P., R. C. C.), Sutton, Surrey, SM2 5PX, United Kingdom; Department of Endocrinology, Chelsea Hospital for Women, London, SW3 6LT, M. D.; United Kingdom; Department of Pharmacology and Experimental Therapeutics, University of Maryland, School of Medicine, Baltimore, Maryland 21201 (A. B.); Ludwig Institute for Cancer Research (London Branch) (R. C. C.) and St. George’s Hospital [J.-C. C., G. H.], London, SW17, United Kingdom

ABSTRACT

4-Hydroxyandrostenedione (4-OHA), a potent new aromatase inhibitor, was given i.m. (500-1000 mg) to 58 patients with advanced postmenopausal breast cancer. Of 52 assessable patients 14 responded (27%), in 10 (19%) the disease stabilized, and in 28 (54%) the disease progressed. Sterile abscesses occurred at the injection site in 6 patients and painful lumps were found in a further 3 patients. Two patients developed allergic-type reactions and 4 developed lethargy, suspected to be treatment induced. Plasma estradiol levels were suppressed from a mean of 7.2 ± 0.8 (SE) pg/ml before treatment to 2.6 ± 0.2, 2.7 ± 0.2, and 2.8 ± 0.3 pg/ml after 1, 2, and 4 months, respectively, of treatment and remained suppressed in patients whose disease relapsed. No significant fall in progesterone levels was seen. Similarly, dehydroepiandrosterone sulfate, sex hormone binding globulin, and gonadotrophin levels were unaltered after 6 months of treatment. Plasma 4-OHA levels were measured in a radioimmunoassay for androstenedione after Chromatographie separation of 4-OHA from androstenedione. Drug concentrations ranged from 0.7 to 23.2 (7.8 ± 1.1) ng/ml after 2 months on treatment. 4-OHA is an effective drug in the management of postmenopausal patients with breast cancer and does not produce notable systemic side effects.

INTRODUCTION

Estrogen deprivation is thought to be a major mechanism of the endocrine treatment of breast cancer. Approximately 30% of postmenopausal patients with advanced breast cancer respond to current modes of endocrine therapy. The source of estrogen in these patients is from conversion of circulating androgens by the estrogen synthetase enzyme complex, aromatase, in peripheral tissues (1). Our approach is to deprive tumors of estrogen with compounds which selectively inhibit this enzyme. Since our first report in 1973 we have identified a number of aromatase inhibitors of which 4-OHA (2) (The material used in this study was supplied by Ciba-Geigy, Basle, Switzerland; 4-OHA; CGP 32349.) is the most potent inhibitor of human placental aromatase (2, 3) (K-,0.15 μM). 4-OHA treatment inhibits peripheral aromatization in rhesus monkeys (4), suppresses ovarian estrogen secretion in rats (3), and causes regression comparable to ovariectomy of carcinogen-induced mammary tumors in these animals (5).

Our preliminary communication on the first use of this drug in humans documented response in 4 of 11 postmenopausal women with advanced breast cancer (6). We report here a larger Phase II study confirming the biological activity of 4-OHA in advanced postmenopausal breast cancer, and toxicity findings are discussed. The endocrine effects and plasma drug levels of 4-OHA are also described.

PATIENTS AND METHODS

Patient Selection. All patients selected were postmenopausal or surgically ovariectomized women who had been shown to have primary breast cancer and assessable (by International Union Against Cancer criteria) progressive metastatic disease (7). Patients were included irrespective of the ER status of their primary or metastatic tumors. "ER positive" tumors were designated to be those which bound more than 15 fmol estradiol per mg cytosol protein as measured by a previously described method (8). No patient had received endocrine or chemotherapy within 4 weeks of the start of treatment. Exclusion criteria included a second primary tumor; significant renal (blood urea nitrogen, >12 mm), hepatic (bilirubin, >17 μM), or cardiac disease; rapidly progressive life threatening metastases; a life expectancy of <6 weeks; adverse psychological factors or refusal to give written informed consent. Informed consent was obtained from all patients, and the study was approved by the Royal Marsden Hospital Ethics Committee; the Office for Protection from Research Risks, NIH; and Human Volunteers Research Committee, University of Maryland School of Medicine, Baltimore, MD. Patients were free to withdraw from the trial at any time.

Clinical Protocol. All patients were fully staged by previously published methods (9) at the beginning of treatment and again at 2, 6, and 12 months and 6 monthly intervals thereafter. They were seen on an outpatient basis weekly for the first 8 weeks and then once a month. Investigations included a history, full clinical examination by at least 2 physicians with bidimensional measurement of all lesions, full blood count, urea, electrolytes, calcium, phosphate, liver function tests, γ-glutamyl transferase on each visit and chest X-ray, bone scan, limited skeletal survey, liver ultrasound, and photography every 2 months. Response to treatment was measured according to the standard criteria of the International Union Against Cancer (7). In the case of bidimensional lesions response was defined either as disappearance of all lesions or a decrease by 50% or more in the sum of the products of the diameters of individual lesions with no lesion increasing in size. In each case no new lesions should have appeared. Progression was defined as either the appearance of new lesions or an increase of 25% or more in the sum of the products of the diameters of individual lesions or an increase of less than 25% made additional treatment necessary. In situations such as infiltration of the breast, liver involvement, or mediastinal lymphadenopathy objective regression was classified as a 50% or greater decrease in that measurement which was regarded as being in excess of that usual for the site under consideration.

Initially patients received 4-OHA at a dose of 500 mg once weekly in alternate buttocks by i.m. injection. The dose chosen was approximately 0.2% of the acute 10% lethal dose obtained in mice during preclinical toxicity studies. Later in 11 patients, mainly nonresponders, the dose was increased to 1000 mg (500 mg in each buttock weekly). The drug, supplied as a sterile microcrystalline powder and stored at 4°C, was suspended in physiological saline (500 mg/4 ml) immediately prior to administration. Injection sites were varied to avoid local side effects. Where these became severe, treatment was decreased in frequency or stopped. In the event of disease progression, treatment was immediately discontinued, the patient was restaged (as above), and alternative treatment was considered. Patients who died or whose treatment was discontinued before 4 weeks of treatment were excluded from analysis. Patients on treatment for less than 8 weeks were not assessable.

Toxicity and side effects were assessed by routine blood tests, clinical examination when visiting the hospital, and a standard questionnaire.
completed each week by the patient and a district nurse. Particular attention was paid to the development of local toxicity and to symptoms or signs suggestive of hormonal side effects.

Hormone Measurement. Estradiol, estrone, LH, FSH, and DHAS were measured by radioimmunoassay according to previously described methods with minor modifications (6, 10–12). Cross-reaction of 4-OHA in the estradiol assay was <1 x 10^{-4}% and was avoided in the estrone assay by the chromatography of ether extracts on Lipidex 5000 (Packard) using chloroform:hexane:methanol (50:50:1) as eluent. SHBG binding capacity was measured by the two-tier column method as described previously (13).

Blood was taken from patients before therapy was instituted and during treatment, shortly before each injection of 4-OHA, and at a similar time of day for each patient. Plasma was stored at −20°C until analysis. All samples from the same patient were analyzed in the same assay batch.

Drug Measurement. Ether extracts of plasma were subjected to chromatography on Lipidex 5000 in trimethylpentane:isopropyl alcohol (1:5) which separated androstenedione from 4-OHA. The levels of 4-OHA were then measured, utilizing its 25% cross-reaction in a previously described androstenedione assay (14). Full details of this methodology are to be published elsewhere.

RESULTS

Response to Therapy. Six of the 58 patients entered into the trial were not assessable because 4-OHA was administered for less than 3 weeks. Table 1 gives the pretreatment characteristics of all the patients entered. Most patients were heavily pretreated, 29 (50%) having received at least 2 previous endocrine therapies. Only 8 patients had not received any previous endocrine therapy.

Overall evaluation of 52 assessable patients (Table 2) revealed that 14 (27%) had objective complete (4 patients) or partial (10 patients) responses to treatment. In 10 (19%) patients the disease stabilized for at least 8 weeks on therapy and in 28 (54%) patients the disease progressed. Of the 22 ER positive patients, 6 responded to 4-OHA, 3 had static disease, and in 13 the disease progressed. Of the 3 patients with ER negative tumors 1 responded and 2 had progressive disease. Twenty-four patients had previously responded to endocrine therapy, and 7 of these responded to 4-OHA, while in 3 the disease stabilized. There was no difference (P = 0.4) in disease free interval (i.e., the time from primary diagnosis to first relapse) between responders and nonresponders. Response by site of disease is shown in Table 3. The responses seemed to occur most often in soft tissue and lymph nodes affected by breast cancer, with only 1 response in a visceral site. There were no responses in liver metastases (n = 11). Only 4 of 35 (11%) patients' skeletal metastases responded although bone pain was alleviated in 5 of 8 patients with this symptom. Of the 14 patients who responded to 4-OHA, 4 have since relapsed at 3, 4, 4, and 13 months. Ten patients remain in remission for periods between 2 and 18 months. Mean duration of response and response to subsequent therapy cannot yet be adequately evaluated.

Toxicity. Sterile abscesses occurred at the injection site in 6 patients (in 4 only after the dose had been increased to 1000 mg) and moderately painful lumps occurred in a further 3 patients. The severity of the abscesses caused treatment to be discontinued in 2 patients and the frequency of injections was decreased in 2 others. Four patients experienced transient, mild lethargy which appeared to be treatment related. One patient who had been on treatment for 6 months developed an anaphylactoid reaction immediately after an injection. Perioral edema which resolved within 24–48 h occurred in 1 patient. No other systemic toxicity was noted.

Endocrine Effects. Plasma estradiol levels were suppressed from 7.2 ± 0.8 (SE) pg/ml before treatment to 2.6 ± 0.2 pg/ml after 1 month of treatment. There was no further change in estradiol levels after 2 or ≥4 months of treatment (Fig. 1). There was no significant difference between responders and nonresponders.
nonresponders in the suppression of estradiol levels (P > 0.1) (Fig. 2).

Plasma levels of estrone, DHAS, SHBG binding capacity, LH, and FSH after at least 1 month of treatment are shown in Fig. 2. Mean pretreatment levels were; estrone, 26.5 ± 4.2 pg/ml; DHAS, 0.82 ± 0.19 μg/ml; SHBG, 12.2 ± 1.6 ng testosterone/ml; LH, 47.6 ± 6.2 IU/liter; and FSH, 49.8 ± 4.3 IU/liter. There was no significant fall or rise in any of these hormones (paired t tests). The mean estrone level fell to 88.2% of baseline values but this fall was not statistically significantly different from pretreatment levels (P > 0.1).

Drug Levels. Drug concentrations in plasma taken from 22 patients after 2 months of therapy and 1 week after their previous injection, ranged from 0.7 to 23.2 (7.8 ± 1.1) ng/ml.

DISCUSSION

Approximately 30–40% of postmenopausal patients with advanced breast cancer respond to hormonal manipulation if selected randomly without regard to the ER status of their tumors (15). AG is an example of an agent in current clinical use (16, 17). It is thought to exert its antitumor effect by suppressing circulating estrogens through its inhibitory action on the enzyme complex aromatase (18). However, it also inhibits its earlier steps in the steroid biosynthetic pathway (19), depleting corticosteroids, and requiring their replacement (20). In addition, AG causes substantial drowsiness in approximately 40% of patients and a morbilliform, maculopapular skin rash in approximately one-third of patients (16). Our study addressed the question of whether a more powerful and selective aromatase inhibitor than AG could produce improved response rates without adverse side effects.

The observed overall response rate of 27% is similar to other major forms of endocrine treatment although there was a bias in favor of ER positive tumors in our study (ER positive, 22; ER negative, 3; unknown, 27) which might have favored higher response rates (21). However, most patients had advanced metastatic disease (average, 2.5 metastatic sites per patient) and one-half had already received several endocrine therapies prior to receiving 4-OHA. A number of these patients had been resistant to their previous therapy which would reduce the likelihood of their response to subsequent endocrine treatment (15). In addition the optimum dose, route of administration, and dose scheduling have not yet been determined. A comparison of 4-OHA to other forms of endocrine therapy is now needed to define its exact role in breast cancer management.

As regards toxicity, the most frequent side effect was development of local sterile abscesses and moderately painful lumps at the injection sites. The incidence of painful lump decreased as the technique of administration was modified. A slow rate of injection through a narrow bore needle together with careful selection of the injection site, tended to alleviate this problem. This is in keeping with the experience of other investigators using parenteral medroxyprogesterone acetate, another steroid used in patients with advanced breast cancer (22). Local tolerability is not a problem with the lower dosage regimens now being investigated. Lethargy is a common symptom in patients with malignant disease and its occurrence in four of our patients is difficult to evaluate. The two allergic-type reactions noted both occurred in patients with known previous drug allergies. The possibility that the cause of these was an excipient used in the formulation is being investigated.

We have reported previously (6) that plasma estradiol levels were suppressed by greater than 50% by a single 500-mg i.m. injection of 4-OHA and that this suppression was maintained for at least 1 week. In the present study this marked suppression was confirmed and it was demonstrated that there is no escape from suppression as treatment is continued. Since similar suppression of estradiol was seen in responders and nonresponders it is likely that any lack of tumor response is due to differences in estrogen dependence in the tumors and not to ineffective suppression of estradiol.

The failure of 4-OHA to suppress estrone was an unexpected finding since both estradiol and estrone are formed from the conversion of androgenic precursors (testosterone and androstenedione, respectively) and the two estrogens are interconvertible by 17βOHDSDH. 4-OHA inhibits conversion of both androgenic precursors to their respective estrogens with equal efficiency in human placental microsomes. Aminoglutethimide which is an aromatase inhibitor by virtue of its interaction with cytochrome P-450 (18) reduces plasma estradiol and estrone in a parallel manner (23). The lack of estrone suppression in this study is unlikely to be due to cross-reaction of 4-OHA in the assay since the column chromatography system used prior to the estrone assay was designed specifically to avoid this potential problem. 4-Hydroxyestrone is a minor metabolite of 4-OHA in vitro (24) and is converted very rapidly to 4-methoxyestrone (25) which does not coelute with estrone from the Lipidex columns and is therefore unlikely to interfere in the...
analysis. The validity of the result is supported by previous observations in rats where suppression of estradiol synthesis by 4-OHA was markedly greater than that of estrone (3, 26). This nonparallel suppression of the estrogens by 4-OHA might be expected to occur if the drug caused inhibition of 17βOHS DH. Although the drug appears to interact with that enzyme [4-hydroxytestosterone is a metabolite of 4-OHA in rhesus monkeys (27)], the inhibition of 17βOHS DH by 4-OHA in vitro is about 100-fold less effective than that of aromatase (28). Although the explanation for the result remains unknown, these results indicate that inhibition of estradiol but not estrone synthesis is important for successful endocrine treatment of postmenopausal breast cancer.

Plasma DHAS levels are a relatively stable marker of adrenal activity and are closely related to urinary free cortisol levels (20). Since 4-OHA therapy did not affect DHAS it is unlikely that it has a significant effect on adrenal function.

Gonadotrophin levels were unaffected by 4-OHA treatment in patients although in ovariectomized rats levels of LH and FSH were suppressed after administration of 4-OHA (26) which was probably due to the slight androgenic activity of the compound (3). Higher doses of 4-OHA in patients may suppress gonadotrophins; however, peripheral aromatase is not under gonadotrophin control in postmenopausal women. These results indicate that at the dose used in this study this is unlikely to be a significant mechanism of action in these patients. Lack of significant androgenic activity is confirmed by our observation that therapy does not alter SHBG binding capacity.

Measurable 4-OHA plasma concentrations 1 week after the previous injection suggest that a depot of drug is formed at the injection site. Slow release of the compound from this site together with its rapid metabolism and clearance rate (27) may account for the low levels found. We have previously reported (29) that 4-OHA is both a competitive, reversible inhibitor of aromatase as well as a slower irreversible suicide inhibitor. This latter effect together with the depot formed at the injection site may account for the sustained suppression of estradiol despite low drug levels.

In conclusion, 4-OHA, a potent new aromatase inhibitor, is capable of markedly reducing plasma estradiol levels and producing tumor regression in postmenopausal patients with advanced breast cancer. This is the first direct evidence that selective inhibition of estradiol synthesis is important in the endocrine treatment of postmenopausal breast cancer. A major advantage of its use over other forms of endocrine therapy is the apparent absence of significant systemic toxicity. Optimum dose, route of administration, and dose scheduling are now being investigated.

ACKNOWLEDGMENTS

We thank Dr. Sue Ashley for computer analysis, Anthony Murphy for dispensing assistance, and Marion Hill for estradiol, estrone, and drug level measurements. We also thank Dr. M. Jarman and Professor S. L. Jeffcoat for helpful discussions and Ciba-Geigy for their assistance and supply of 4-hydroxyandrostenedione. We also thank the Cancer Research Campaign, Phase I committee, for funding the toxicology studies and providing a clinical fellowship to P. G.

REFERENCES


Treatment of Advanced Postmenopausal Breast Cancer with an Aromatase Inhibitor, 4-Hydroxyandrostenedione: Phase II Report


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/46/9/4823

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.